Angioplasty with nitinol stents shows promise as PAD treatment

Percutaneous transluminal angioplasty with nitinol stenting offers promise as a treatment for peripheral artery disease or critical limb ischemia, according to results of a new trial published in Catheterization and Cardiovascular Interventions, a Wiley journal published on behalf of the Society for Cardiovascular Angiography and Interventions. The XCELL trial proved that the procedure was safe on patients and successfully worked to boost wound healing, reduce pain and cut back on the need for amputation as a treatment option. The trial, which used Abbott's Xpert stent, involved stenting of the infrapopliteal arteries. And the 12-month wound healing rate with nitinol stenting generated results similar to the more invasive open heart surgery procedures. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.